Роль эпигенетических факторов в патогенезе нейрофиброматоза 1-го типа

Обложка

Цитировать

Полный текст

Об авторах

Р. Н. Мустафин

ФГБОУ ВО «Башкирский государственный университет».

Автор, ответственный за переписку.
Email: fake@neicon.ru
Республика Башкортостан, 450076 Уфа, ул. Заки Валиди, 32. Россия

Э. К. Хуснутдинова

ФГБОУ ВО «Башкирский государственный университет»; ФГБУН Институт биохимии и генетики Уфимского научного центра РАН.

Email: elzakh@mail.ru
Республика Башкортостан, 450054 Уфа, проспект Октября, 71. Россия

Список литературы

  1. Duong T., Sbidian E., Valeyrie-Allanore L. et al. Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980–2006 in France. Orphanet J Rare Dis 2011;6:18–26.
  2. Gregorian C., Nakashima J., Dry S. et al. PTEN dosage is essential for neurofibroma development and malignant transformation. PNAS 2009;106(46):19479–84.
  3. Melean G., Hernandez A.M., Valero M.C. et al. Monozygotic twins with neurofibromatosis type 1, concordant phenotype and synchronous development of MPNST and metastasis. BMC Cancer 2010;10:407–12.
  4. Ponti G., Losi L., Martotana D. et al. Clinico-pathological and biomolecular findings in Italian patients with multiple cutaneous neurofibromas. Hered Cancer in Clin Pract 2011;9:6–15.
  5. Brinkman J., Bron J., Wuisman P. et al. The correlation between clinical, nuclear and histologic findings in a patient with Von Recklinghausen’s disease. World J Surg Oncol 2007;5:130–7.
  6. Laycock-van Spyk S., Thomas N., Cooper D., Upadhyaya M. Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and patho genesis. Hum Genomics 2011;5(6): 623–90.
  7. Patil S., Chamberlain R.S. Neoplasms associated with germline and somatic NF1 gene mutations. Oncologist 2012;17(1):101–16.
  8. Chai G., Liu N., Ma J. et al. MicroRNA10b regulated tumorigenesis in neurofibromatosis type 1. Cancer Sci 2010;101(9):1997–2004.
  9. Yap Y.S., McPherson J.R., Ong C. et al. The NF1 gene revisited – from bench to bedside. Oncotarget 2014;5(15); 5873–92.
  10. Vandenbrucke I. Identification and characterization of neurofibromatosis type 1 splice variants. 2004.
  11. Дрозд О.В., Бабенко О.В., Семячкина А.Н. и др. Разработка подходов к ДНКдиагностике нейрофиброматоза 1-го типа в России. Медицинская генетика 2005;4(7):322–6. [Drozd O.V., Babenko O.V., Semyachkina A.N. et al. Development of approaches to DNA diagnostics of type 1 neurofibromatosis in Russia. Meditsinskaya genetika = Medical Genetics 2005;4(7):322–6. (In Russ.)].
  12. Мустафин Р .Н., Бермишева М.А., Хуснутдинова Э.К. Особенности нейрофиброматоза 1-го типа в Республике Башкортостан. Медицинская генетика 2015;14(6): 29–35. [Mustafin R.N., Bermisheva M.A., Khusnutdinova E.K. Features of type 1 neurofibromatosis in the Republic of Bashkortostan. Meditsinskaya genetika = Medical Genetics 2015;14(6):29–35. (In Russ.)].
  13. Ratner N., Miller S.J. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat RevCancer 2015;15(5):290–301.
  14. Sabbagh A., Pasmant E., Laurendeau I. et al. Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. Hum Mol Gen 2009;18(18): 2768–78.
  15. Eisenbarth I., Beyer K., Krone W., Assum G. Toward a survey of somatic mutation of the NF1 gene in benigh neurofibromas of patients with neurofibromatoss type 1. Am J Hum Genet 2000;66(2):393–401.
  16. Stevenson D.A., Zhou H., Ashrafi S. et al. Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet 2006;79(1):143–8.
  17. Boyd K.P., Korf B.R., Theos A. Neurofibromatosis type 1. J Am Acad Dermatol 2009;61(1):1–16.
  18. MсGillicuddy L.T., Fromm J.A., Hollstein P.E. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 2009;16(1):44–54.
  19. Gutmann D.H., Giovannini M. Mouse models of neurofibromatosis 1 and 2. Neoplasia 2002;4(4):279–90.
  20. Hawes J.J., Tuskan R.G., Reilly K.M. Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies. Neurogenetics 2007;8(2):121–30.
  21. Jouhilahti E.M., Peltonen S., Heape A.M., Peltonen J. The pathoetiology of neurofibromatosis 1. Am J Pathol 2011;178(5):1932–9.
  22. Huppi K., Volfovsky N., Mackiewicz M. et al. MicroRNAs and genomic instability. Semin Cancer Biol 2007;17(1):65–73.
  23. Bottillo I., Luca A., Schirinzi A. et al. Functional analysis of splicing mutations in exon 7 of NF1 gene. BMC Med Genet 2007;8:4–13.
  24. Zhou H., Hinman M., Barron V. et al. Hu proteins regulate alternative splicing by inducing localized histone hyperacetylation in an RNA-dependent manner. PNAS 2007;108(36):627–35.
  25. Горбунова В.Н., Имянитов Е.Н., Ледащева Т .А. и др. Молекулярная неврология. Часть III. Опухоли головного мозга, онкогены и антионкогены. Под ред. А.А. Скоромца. СПб.: Интермедика, 2004. С. 219–232. [Gorbunova V.N., Imyanitov E.N., Ledashcheva Т .А. et al. Molecular neurology. Part III. Tumors of the brain, oncogenes and anti-oncogenes. Ed. A.A. Skoromets. Saint Petersburg: Intermedika, 2004. Pp. 219–232. (In Russ.)].
  26. Wimmer K., Callens T., Wernstedt A., Messiaen L. The NF1 gene contains hotspots for L1 endonuclease-dependent de novo insertion. PLoS Genet 2011;7(11):e1002371.
  27. Ayarpadikannan S., Lee H.E., Han K., Kim H.S. Transposable element-driven transcript diversification and its relevance to genetic disorders. Gene 2015;558(2):187–94.
  28. Патрушев Л.И., Минкевич И.Г. Проблема размера геномов эукариот. Успехи биологической химии 2007;47:293–370. [Patrushev L.I., Minkevich I.G. The problem of the size of the genomes of eukaryotes. Uspekhi biologicheskoy khimii = Advances in Biological Chemistry 2007;47:293–370. (In Russ.)].
  29. Козлов В.А. Метилирование ДНК клетки и патология организма. Медицинская иммунология 2008;10(4): 307–18. [Kozlov V.A. Methylation of cell DNA and pathology of the body. Meditsinskaya immunologiya = Medical Immunology 2008;10(4):307–18. (In Russ.)].
  30. Jeong S.Y., Park S.J., Kim H.J. The spectrum of NF1 mutations in Korean patients with neurofibromatosis type 1. J Korean Med Sci 2006;21(1):107–12.
  31. Fishbein L., Eady B., Sanek N. et al. Analysis of somatic NF1 promoter methylation plexiform neurofibromas and Schwann cells. Cancer Genet Cytogenet 2005;157(2):181–6.
  32. Garcia-Linares C., Fernandez-Rodriguez J., Terribas E. et al. Dissecting loss of heterozygosity (LOH) in neurofibromatosis type 1-associated neurofibromas: importance of copy neutral LOH. Hum Mutat 2011;32(1):78–90.
  33. De Raedt T.D., Maertens O., Chmara M. et al. Somatic loss of wild type NF1 allele in neurofibromas: comparison of NF1 microdeletion and non-microdeletion patients. Genes Chromosomes Cancer 2006;45(10):893–904.
  34. Stewart D.R., Pemov A., van Loo P. et al. Mitotic recombination of chromosome arm 17q as a cause of loss of heterozygosity of NF1 in neurofibromatosis type 1-asso ciated glomus tumors. Genes Chromosomes Cancer 2012;51(5):429–37.
  35. Geller M., Ribeiro M.G., Araújo A.P. et al. Serum IgE levels in neurofibromatosis 1. Int J Immunogenet 2006;33(2):111–5.
  36. Chen S., Burgin S., McDaniel A. et al. NF1–/– schwann cell-conditioned medium modulates mast cell degranulation by c-Kit-mediated hyperactivation of phosphatidylinositol 3-kinase. Am J Pathol 2010;177(6):3125–32.
  37. Horvath S. DNA methylation age of human tissues and cell types. Genome 2013;14(10):115.
  38. Nissan M.H., Pratilas C.A., Jones A.M. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res 2014;74(8):2340–50.
  39. Holzel M., Huang S., Koster J. et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010;142(2): 218–29.
  40. Рунов А.Л., Вонский М.С., Михельсон В.М. Уровень метилирования ДНК и длина теломер как основа для построения модели биологических часов старения. Цитология 2015;57(3):192–6. [Runov A.L., Vonskiy M.S., Mikhel’son V.М. The level of DNA methylation and the length of telomeres as a basis for constructing a model of biological aging hours. Tsitologiya = Cytology 2015;57(3):192–6. (In Russ.)].
  41. Ванюшин Б.Ф. Эпигенетика сегодня и завтра. Вавиловский журнал генетики и селекции 2013;17(4/2):805–32. [Vanyushin B.F. Epigenetics today and tomorrow. Vavilovskiy zhurnal genetiki i selektsii = Vavilov Journal of Genetics and Breeding 2013;17(4/2):805–32. (In Russ.)].
  42. Horan M.P., Cooper D.N., Upadhyaya M. Hypermethylation of the neurofibromatosis type 1 (NF1) gene promoter is not a common event in the inactivation of the NF1 gene in NF1-specific tumours. Hum Genet 2000;107(1):33–9.
  43. Harder A., Rosche M., Reuss D.E. et al. Methylation analysis of the neurofibromatosis type 1 (NF1) promoter in peripheral nerve sheath tumors. Eur J Cancer 2004;40(18):2820–8.
  44. Gutmann D.H., McLellan M.D., Hussain I. et al. Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. Genome Res 2013;23(3):431–9.
  45. Calin G.A., Dumitru C.D., Shimizu M. et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002;99(24):15524–9.
  46. Gozuacik D., Akkoc Y., Ozturk D.G., Kocak M. Autophagy-regulating microRNAs and cancer. Front Oncol 2017;7:65.
  47. Sedani A., Cooper D.N., Upadhyaya M. An emerging role for microRNAs in NF1 tumorigenesis. Human Genomics 2012;6:23–32.
  48. Garcia-Orti L., Cristobal I., Cirauqui C. et al. Integration of SNP and mRNA arrays with microRNA profiling reveals that miR-370 is upregulated and targets NF1 in acute myeloid leukemia. PLoS One 2012;7(10):e47717.
  49. Paschou M., Doxakis E. Neurofibromin 1 is a miRNA target in neurons. PLoS One 2012;7(10):e46773.
  50. Stark M.S., Bonazzi V.F., Boyle G.M. et al. MiR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. Oncotarget 2015;6(19):17753–63.
  51. Ling H., Fabbri M., Calin G.A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013;12(11): 847–65.
  52. Pasmant E., Sabbagh A., Masliah-Planchon J. et al. Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1. J Natl Cancer Inst 2011;103(22):1713–22.
  53. Mubotter T., Kluwe L., Hogel J. et al. Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions. BMC Med Genet 2012;13:98.
  54. Li Z., Yu X., Shen J. ANRIL: a pivotal tumor suppressor long non-coding RNA in human cancers. Tumour Biol 2016;37(5):5657–61.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ,


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 57560 от  08.04.2014.